SEHK:9926Biotechs
A Look At Akeso (SEHK:9926) Valuation After New Cadonilimab Approval In Colorectal Cancer
Akeso (SEHK:9926) has drawn fresh attention after its Cadonilimab Injection received implicit approval as neoadjuvant and adjuvant monotherapy in resectable colorectal cancer with high microsatellite instability or mismatch repair deficiency.
See our latest analysis for Akeso.
Akeso's HK$120.0 share price has been volatile, with a 1 day share price return of 4.35% after the Cadonilimab update, against a 30 day share price return that is down 18.20%. At the same time, the 1 year total...